Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Martin Bergman1, Namita Tundia2, Naomi Martin2, Jessica L. Suboticki2, Jayeshkumar Patel2, Debbie Goldschmidt3, Yan Song3* and Grace C. Wright4

Abstract

Background: In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs). This post hoc analysis of SELECT-CHOICE, a phase 3 clinical trial, evaluated the impact of UPA vs abatacept (ABA) with background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on PROs in patients with RA with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR).

Methods: Patients in SELECT-CHOICE received UPA (oral 15 mg/day) or ABA (intravenous). PROs evaluated included Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS), patient’s assessment of pain by VAS, Health Assessment Questionnaire Disability Index (HAQ-DI), morning stiffness duration and severity, 36-Item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Impairment (WPAI), and EQ-5D 5-Level (EQ-5D-5L) index score. Least squares mean (LSM) changes from baseline to weeks 12 and 24 were based on an analysis of covariance model. Proportions of patients reporting improvements ≥ minimal clinically important differences (MCID) were compared using chi-square tests.

Results: Data from 612 patients were analyzed (UPA, n=303; ABA, n=309). Mean age was 56 years and mean disease duration was 12 years. One-third received ≥2 prior bDMARDs and 72% received concomitant methotrexate at baseline. At week 12, UPA- vs ABA-treated patients had significantly greater improvements in PtGA, pain, HAQ-DI, morning stiffness severity, EQ-5D-5L, 2/4 WPAI domains, and 3/8 SF-36 domains and Physical Component Summary (PCS) scores (P<0.05); significant differences persisted at week 24 for HAQ-DI, morning stiffness severity, SF-36 PCS and bodily pain domain, and WPAI activity impairment domain. At week 12, significantly more UPA- vs ABA-treated patients reported improvements ≥ MCID in HAQ-DI (74% vs 64%) and SF-36 PCS (79% vs 66%) and 4/8 domain scores (P<0.05).

Conclusions: At week 12, UPA vs ABA treatment elicited greater improvements in key domains of physical functioning, pain, and general health and earlier improvements in HAQ-DI. Overall, more UPA- vs ABA-treated patients
Introduction

Patients with rheumatoid arthritis (RA) frequently experience pain, fatigue, and impaired physical functioning that may impact their health-related quality of life (HRQOL) and ability to work and participate in daily activities [1–4]. Relief of pain is an important treatment outcome for patients and a primary reason for seeking medical care [2]. The restrictions on patients’ daily work and social activities due to symptom burden have a significant impact on their financial and social well-being [2, 4, 5]. With a significant burden on HRQOL, treatment decisions are recommended as a shared decision between the patient and physician [6]. Guidelines recommend conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate (MTX), as a first-line treatment strategy and biologic DMARDs (bDMARDs) like abatacept (ABA), anti-TNF inhibitors, or Janus kinase (JAK) inhibitors as second-line therapy options [6]. Unfortunately, up to 43% of patients do not respond to first-line csDMARD therapy and as many as two-thirds who receive bDMARDs have an inadequate response (bDMARD-IR) after 1 year of therapy [7, 8]. Thus, this population is difficult to adequately treat and, as such, exhibits marked increases in healthcare resource utilization; bDMARD-IR patients experienced up to 7-fold increases in hospital length of stay, admissions, and emergency department visits as compared with patients that responded to bDMARD therapy [7].

Discordance between healthcare provider and patient perceptions of disease exists [9, 10], especially in patients continuing to experience pain despite inflammation being controlled [11] or by those continuing to experience fatigue despite achieving remission [12]. To fully understand the disease burden and benefits of treatment from the perspective of patients with RA, it is important to include PROs as part of clinical trials and evaluation of treatment efficacy. This is especially true for patients with inadequate response to csDMARDs (csDMARD-IR) and bDMARD-IR. Treatment with upadacitinib (UPA), an oral JAK inhibitor, has resulted in clinically meaningful improvements in patient-reported outcomes (PROs), including in key components of pain, fatigue, and physical functioning [13–15]. Improvements in PROs have been observed with UPA as monotherapy [16] and in combination with MTX [13, 15]. Improvements were equivalent to or greater than with anti-TNF inhibitor adalimumab [14]. In patients with inadequate response or intolerance to MTX, UPA treatment significantly improved patient-reported pain and physical functioning [13, 14]. ABA is commonly prescribed as a second-line bDMARD for the treatment of RA, and studies have shown that ABA treatment improves PROs, yet comparisons of ABA to JAK inhibitors are limited [17–22]. Further research is needed to guide treatment decisions, particularly from the patients’ perspective. This post hoc analysis evaluated the impact and benefits of treatment with oral UPA versus intravenous (IV) ABA on PROs at weeks 12 and 24 in a head-to-head comparison in patients with active RA and bDMARD-IR in SELECT-CHOICE [23].

Materials and methods

Study design and participants

Full details of the study design of SELECT-CHOICE (NCT03086343) were previously reported [23]. This study was a phase 3, double-blind, randomized clinical trial in patients with active bDMARD-IR RA currently receiving background csDMARD therapy. Patients ≥18 years of age with moderately to severely active RA for ≥3 months on a stable background of csDMARD therapy (≥3 months prior to study entry) were randomized double-blind to receive either oral UPA (15 mg once daily) with IV placebo or IV ABA and oral placebo. This study was not placebo-controlled in that, despite patients receiving an oral or IV placebo, patients knew that they were receiving an active drug, however, they were unaware of which drug they were receiving. Both IV placebo and ABA treatments were administered on day 1 and at weeks 2, 4, 8, 12, 16, and 20 at doses of 500, 750, or 1000 mg, depending on patient weight (<60 kg, 60–100 kg, or >100 kg, respectively). Concomitant use of ≤2 of the following csDMARDs was permitted: MTX, sulfasalazine, hydroxychloroquine, chloroquine, or leflunomide; combination of MTX and leflunomide was not permitted. Eligible patients had no previous exposure to ABA. Data on the primary and ranked secondary outcomes of this study have been published previously [23]. The protocol was approved by independent ethics committee or institutional review board at all study sites. All participants provided written, informed consent prior to enrollment. The registered
clinical trial was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and is consistent with the International Conference on Harmonization Good Clinical Practice and Good Epidemiology Practices, and all applicable local regulatory requirements. All patient data were de-identified and complied with patient confidentiality requirements.

**Patient-reported outcomes**

Several PROs were collected to assess the impact of UPA on the patients’ symptoms and HRQOL. The Patient Global Assessment of Disease Activity (PtGA) by visual analog scale (VAS) assessed overall disease severity (range 0–100 mm), with higher scores indicating greater disease activity [24–26]. Pain was measured with the Patient’s Assessment of Pain by VAS (range 0–100 mm), wherein higher scores denoted greater pain [24, 25]. The Health Assessment Questionnaire Disability Index (HAQ-DI) assessed physical functioning, and higher scores (range 0–3) indicated greater physical impairment [24, 27]. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) evaluated fatigue on a scale of 0–52, with higher scores indicating less fatigue [25, 28]. The EQ-5D 5-level (EQ-5D-5L) assessed perceptions of overall health, and higher index scores indicated better health [29]. Morning stiffness was reported as duration in minutes, and stiffness severity on a scale of 0–10, with higher values indicating longer lasting or worse morning stiffness [24, 30]. The Work Productivity and Activity Impairment (WPAI) assessment was also used and consists of 4 domains: absenteeism, presenteeism, overall work impairment, and activity impairment. WPAI domain scores were expressed as impairment percentages (scale 0–100%), with higher values indicating greater impairment [31]. The 36-Item Short Form Health Survey (SF-36), which consists of 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health), and the composite Physical (PCS) and Mental (MCS) Component Summary scores were also assessed; higher scores on SF-36 (range 0–100) indicated better health and functioning [24, 25, 32, 33].

Table 1 shows the scoring ranges, minimal clinically important difference (MCID) values, and normative values, where available, for each PRO. Pain, PtGA, HAQ-DI, and morning stiffness were assessed at all time points (day 1 and weeks 2, 4, 8, 12, 16, 20, and 24). WPAI was assessed at day 1 and weeks 4, 8, 12, and 24; FACIT-F was assessed at day 1 and weeks 1, 2, 4, 8, 12, 16, and 24; and the SF36 and EQ-5D-5L were assessed at day 1 and weeks 4, 12, and 24.

### Table 1 Patient-reported outcomes measurements and meaningful values

| PRO               | Range       | MCID          | Normative value |
|-------------------|-------------|---------------|-----------------|
| PtGA (VAS)        | 0–100 mm   | ≥−10 mm [18, 24, 25] | ≥20 [ (40)] |
| Pain (VAS)        | 0–100 mm   | ≥−10 mm [24, 25] |                |
| HAQ-DI            | 0–3        | ≥−0.22 units [24, 25] | ≤0.25 unit [41] |

**Morning stiffness**

- **Duration**: Day 1 and weeks 4, 8, 12, and 24.
- **Severity**: Day 1 and weeks 2, 4, 8, 12, 16, 20, and 24.

### Statistical analysis of data

Least squares mean (LSM) changes from baseline to weeks 12 and 24 were assessed based on an analysis of covariance model and comparisons between treatment arms used chi-square tests with significance at the 5% level. The proportion of patients reporting improvements ≥ MCID from baseline through weeks 12 and 24, and those achieving normative values were calculated for UPA and ABA treatment. For each PRO, response rates were only calculated for patients who had non-missing baseline PRO scores and missing values were imputed as non-responses. The incremental numbers needed to treat (NNTs) to demonstrate MCID were calculated as the reciprocal of the response rate differences between UPA and ABA for each PRO at weeks 12.
and 24. WPAI work impairment was only calculated for patients who were employed. Time to response, defined as improvement ≥ MCID, was assessed for pain (VAS), HAQ-DI, and duration and severity of morning stiffness and was assessed by Kaplan-Meier analysis and compared using the log-rank test. The PRO endpoints presented in this manuscript were not ranked secondary endpoints and, thus, were not controlled for multiplicity. As such, nominal P values are provided throughout.

**Results**

**Patient demographics**

The study enrolled and randomized 612 patients (UPA, n=303; ABA, n=309) with a mean age of 56 years and an average RA duration of 12 years (Table 2). Baseline characteristics among the treatment arms were comparable, with nearly one-third of patients enrolled having received 2 or more prior bDMARDs (32%), over 60% having received at least one TNF inhibitor, and over 80% of patients receiving MTX, with or without another csDMARD, at baseline. Over half of the patients enrolled were on an oral steroid at baseline. Baseline PROs were similar between the two treatment groups (Table 3) and reflect the impact of RA on the HRQOL in patients with a long disease duration.

**LSM changes from baseline**

At week 12, UPA treatment resulted in statistically significant improvements in PtGA, pain, HAQ-DI, severity of AM stiffness, EQ-5D-5L, WPAI activity impairment and presenteeism domains, three SF-36 domains (physical functioning, bodily pain, and general health), and the SF-36 PCS score (p<0.05, Table 3) as compared to improvements with ABA. At week 24, changes from baseline were maintained in UPA-treated patients and a significant difference persisted between UPA- and ABA-treated patients in HAQ-DI, severity of AM stiffness, WPAI activity impairment domain, and the SF-36 PCS and bodily pain domain scores; changes from baseline were similar between groups for the remaining PROs.

**Proportion of patients reporting improvements ≥ MCID in PROs at weeks 12 and 24**

Compared with ABA at week 12, significantly more UPA-treated patients reported improvements ≥ MCID in HAQ-DI. Similar proportions of patients reported clinically meaningful improvements in the ability to perform work and daily activities as demonstrated by WPAI scores. Likewise, similar proportions of patients reported improvements ≥ MCID across other PROs (Fig. 1A). Among the SF-36 domain scores, a significantly greater proportion of patients receiving UPA, as compared with ABA, reported improvements ≥ MCID on physical functioning, role physical, bodily pain, and general health (Fig. 2A). Likewise, clinically meaningful improvements in SF-36 PCS scores were reported in significantly more UPA-treated patients (Fig. 1A). Improvements in the other 4 domains were similar between groups. At week 24, more UPA-treated patients reported improvements ≥ MCID in most PROs compared with ABA-treated patients; however, these differences were not statistically significant (Figs. 1B and 2B).

**Proportion of patients achieving normative values in PROs at baseline and weeks 12 and 24**

At baseline, few patients reported having normative PRO scores (i.e., values consistent with those reported by patients without disease; Fig. S1 and S2). Not all PROs assessed in this study have known normative values, thus achievement of normative values is only reported for a subset of PROs. The percentage of patients reporting normative values at baseline, for both UPA and ABA groups, ranged from 1% (SF-36 PCS) to 29% (SF-36 MCS). By week 12, the percentages of UPA- vs ABA-treated patients achieving normative values were significantly greater in PtGA (37% vs 23%),

Table 2  Patient demographics and RA treatment history

| Characteristics                        | UPA 15 mg (n=303) | ABA IVa (n=309) |
|----------------------------------------|-------------------|-----------------|
| Age, mean ± SD                         | 55.3 ± 11.4       | 55.8 ± 11.9     |
| Female, n (%)                          | 249 (82)          | 253 (82)        |
| White, n (%)                           | 288 (95)          | 285 (92)        |
| Duration of RA diagnosis, mean ± SD   | 12.4 ± 9.5        | 11.8 ± 8.3      |
| Number of prior bDMARDs received, n (%)|                   |                 |
| 1                                      | 206 (68)          | 202 (65)        |
| 2                                      | 64 (21)           | 70 (23)         |
| ≥3                                     | 29 (10)           | 35 (11)         |
| Number of prior TNF inhibitors received, n (%)|       |                 |
| 0                                      | 40 (13)           | 36 (12)         |
| 1                                      | 212 (70)          | 198 (64)        |
| 2                                      | 38 (13)           | 64 (21)         |
| 3                                      | 13 (4)            | 10 (3)          |
| ≥4                                     | 0                 | 1 (0.3)         |
| Concomitant csDMARDs at baseline, n (%)|                   |                 |
| MTX alone                              | 223 (74)          | 215 (70)        |
| MTX and other csDMARD                  | 30 (10)           | 38 (12)         |
| csDMARD other than MTX                 | 45 (15)           | 56 (18)         |
| Oral steroid at baseline, n (%)        | 169 (56)          | 158 (51)        |

a ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1000 mg), ABA abatacept, bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic disease-modifying antirheumatic drug. IV intravenous, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation, TNF tumor necrosis factor, UPA upadacitinib
HAQ-DI (18% vs 10%), and EQ-5D-5L (22% vs 13%, Fig. S1). Likewise, a significantly greater proportion of patients receiving UPA reported normative values for SF-36 PCS (17% vs 8%, Fig. S1), physical functioning (21% vs 11%), bodily pain (33% vs 23%), and general health (24% vs 17%) domains (Fig. S2). At week 24, significantly more UPA- vs ABA-treated patients achieved normative PRO scores in PtGA (44% vs 34%), HAQ-DI (23% vs 16%), and SF-36 PCS (21% vs 12%) and role physical (22% vs 16%) and bodily pain (38% vs 29%) domains (p<0.05; Figs. S1 and S2). While more UPA-treated patients achieved normative values in the remaining PROs at week 24 compared to ABA-treated patients, the differences between groups were not statistically significant.
Fig. 1 Proportion of patients reporting improvements ≥ MCID in PROs at weeks 12 (A) and 24 (B). "MCID was defined as reduction of ≥10 mm for PtGA and pain, ≥1 for severity of AM stiffness, reduction of ≥0.22 units for HAQ-DI, increase of ≥4 points for FACIT-F, proxied at one-half standard deviation for duration of AM stiffness, increase of ≥0.05 points for EQ-SD-5L, reduction of 7% in score for WPAI, and increase of ≥2.5 points for SF-36 PCS and MCS. ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg). NNTs are for UPA vs ABA. ABA abatacept, AM morning, EQ-5D-5L (index score), EQ-5D 5-Level, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire Disability Index, IV intravenous, MCID minimal clinically important difference, MCS Mental Component Summary, NNT number needed to treat, PCS Physical Component Summary, PRO patient-reported outcome, PtGA Patient Global Assessment of Disease Activity, SF-36 36-Item Short Form Health Survey, UPA upadacitinib, VAS visual analog scale, WPAI Work Productivity and Activity Impairment. *P<0.05 for UPA vs ABA. P values represent statistical significance between treatment groups.
**Time to treatment response**

The time to response (≥MCID), as measured by HAQ-DI, was significantly shorter for UPA- vs ABA-treated patients (medians: 2 weeks vs 4 weeks, *P*<0.01 [data not shown]). The median time to response was not statistically significantly different for UPA- versus ABA-treated patients in pain (2 weeks vs 4 weeks). There was no difference in the median time to response for morning stiffness severity or morning stiffness duration.
Discussion
JAK inhibitors, including UPA, are a newer class of treatment for RA in comparison to other biologics such as ABA, which have been commonly accepted therapies for patients with RA over the past 20 years. Understanding the efficacy of newer therapies, especially as they compare to more established ones, is important because nearly half of patients do not adequately respond to first-line csDMARDs and up to 66% do not adequately respond to second-line biologics [7, 8]. Thus, these patients represent a population that may be more difficult to treat. The SELECT-CHOICE study is a phase 3 trial that is a direct head-to-head comparison of efficacy, safety, and PROs between UPA and ABA in a bDMARD-IR population [23]. Primary efficacy data demonstrated that UPA was superior to ABA in the change from baseline in DAS28-CRP components and achievement of remission after 12 weeks of treatment; after 24 weeks of treatment, change from baseline in DAS28-CRP components remained numerically greater in UPA- vs ABA-treated patients but were not statistically significant [23]. As a supplement to the clinical efficacy results, analysis of other secondary endpoints showed that both UPA and ABA demonstrated improvement in PROs; however, UPA treatment resulted in more significant and clinically meaningful improvements in PROs at 12 weeks when compared with ABA. Early differences between the treatments were seen in key domains of physical functioning, pain, and general health, with improvements in HAQ-DI observed 2 weeks earlier in UPA- vs ABA-treated patients. In this study, patients treated with UPA achieved significantly greater improvements from baseline in PtGA, pain, HAQ-DI, and FACIT-F as compared with ABA at week 12. Likewise, SF-36 PCS, 3 SF-36 domains (physical functioning, bodily pain, and general health), and 2 WPAI domains (presenteeism and activity impairment) showed significant improvement with UPA vs ABA; at week 12 similar improvements were noted for UPA and ABA in other PROs. At week 24, the change from baseline in HAQ-DI, severity of AM stiffness, WPAI activity impairment domain, and SF-36 PCS and bodily pain domain scores in UPA-treated patients remained statistically significant compared with ABA-treated patients; changes from baseline were similar between groups for the remaining PROs. This study also demonstrated that more patients receiving UPA achieved normative values in PtGA, HAQ-DI, SF-36 PCS, and SF-36 bodily pain domain at both weeks 12 and 24 as compared with ABA-treated patients; UPA-treated patients also had significantly better improvement in the SF-36 role physical domain at week 24 compared with ABA-treated patients. Despite no statistically significant differences in the proportion of patients achieving MCID in these PROs at week 24, these data would suggest that improvements in these PROs with UPA treatment may be more substantial than those improvements observed with ABA treatment based on normative value achievements. The improvements in PROs reported with UPA in this study are similar to those improvements seen with UPA previously in csDMARD-IR and bDMARD-IR patient populations [13–15, 23]. Data from SELECT-COMPARE, which compared UPA, placebo, and adalimumab treatment with a background of MTX at 12 weeks also demonstrated significant improvements with UPA in PtGA, pain, HAQ-DI, morning stiffness severity, FACIT-F, SF-36 PCS, and 6/8 SF-36 domain scores as compared with adalimumab and placebo [14]. Importantly, SELECT-COMPARE enrolled patients who had inadequate response or intolerance to MTX, whereas this study enrolled bDMARD-IR patients, who represent a difficult-to-treat population with a greater, unmet medical need.

Assessment of PROs in chronic disease is key to understanding patient perspectives and should be included when analyzing study drug efficacy. PROs are useful tools to measure the impact of chronic illness on daily living and work abilities because these also impact healthcare resource utilization and overall economic burden of disease. Likewise, PROs can influence treatment decisions and provide a more customized approach to disease management, especially when treatments are comparable [34]. When selecting treatments, time to response, route of administration, and quantity of doses taken per day are also important factors to consider as they may greatly affect patient’s perception of efficacy and overall treatment adherence [35, 36]. Patients with RA frequently experience pain, fatigue, and impaired physical functioning and these may have negative impacts on their HRQOL [1–4]. Fatigue and pain are also associated with reductions in mental well-being and the ability of patients to perform daily activities and maintain employment [4, 37, 38]. In the current study, improvements in physical functioning (HAQ-DI) and severity of morning stiffness were observed as early as 2 weeks after treatment initiation with UPA. After 12 weeks of treatment, greater proportions of UPA- vs ABA-treated patients reported clinically meaningful improvements in physical functioning and in 4 of 8 SF-36 domain and PCS scores. The proportion of UPA- vs ABA-treated patients reporting achieving normative values after 12 weeks treatment was significantly greater in PtGA, physical functioning, general HRQOL by EQ-5D-5L, and SF-36 PCS and 3 of 8 domain scores (i.e., physical functioning, bodily pain, and general health). The proportion of UPA- vs ABA-treated achieving normative values was significantly greater for PtGA, physical functioning, and SF-36 PCS and bodily
pain and role physical domain scores at week 24, with significant proportions of patients also achieving normative values for the SF-36 role physical domain. Similar percentages of patients (over half) treated with UPA or ABA achieved clinically meaningful reductions in work and activity impairment at week 12. At week 24, over 68% of UPA or ABA-treated patients had clinically meaningful improvement in activity impairment; 62% of UPA-treated patients had clinically meaningful improvement in work impairment vs only 49% of ABA-treated patients. Likewise, similar percentages of patients treated with UPA or ABA also achieved clinically meaningful reductions in the key symptom of fatigue. Importantly, patients reported shorter median response times to improvements in physical functioning with UPA treatment compared with ABA. Together, these results suggest that UPA may lead to meaningful early improvements in key PROs that are important to patients, including fatigue, pain, physical functioning, and ability to perform work and daily activities.

There are both strengths and limitations to this study. Strengths of the study include the utilization of several validated PROs that reflect the different aspects of the patient experience. To our knowledge, this is the first clinical study comparing a JAK inhibitor to ABA in a bDMARD-IR population. This study fills the gap by providing important data on patient-perceived efficacy in this population. The use of MCIDs and normative values allow for the data to be clinically meaningful and interpretable for patients and physicians. Blinded and randomized study design allows for unbiased reporting from each patient and mitigates biases due to differences between treatment groups. Limitations of the study include the collection of PROs at fixed visits, sometimes weeks apart, with no day-to-day data available. Prolonged recall of such dynamic symptoms may introduce recall bias that could affect patient perceptions of efficacy [39]. Although patients did receive either IV or oral placebo in combination with active therapy, this trial was not placebo-controlled since patients were aware that they were receiving an active treatment. This may impact on patients’ perception of drug efficacy. The PROs presented here were not multiplicity controlled, ranked secondary endpoints, thus all significance values are nominal. Imputation of missing data as non-response may lead to an underestimation of the true response rate for each PRO. The time frame of this analysis was relatively short (24 weeks), thus additional studies are needed to determine if the patient-reported improvements observed are maintained long-term.

Conclusions
Treatment with UPA or ABA resulted in rapid and clinically meaningful improvements in PROs among bDMARD-IR patients with moderately to severely active RA. Overall, greater improvements from baseline in PROs with UPA vs ABA treatment, especially in the key domains of physical functioning, pain, and general health, were observed after 12 and 24 weeks of treatment. Although the proportion of patients achieving ≥MCID were similar between UPA- and ABA-treated patients at week 24, the numerically greater improvements from baseline in PROs, coupled with higher percentages of patients achieving normative values, suggest that improvement in those PROs may be more substantial with UPA vs ABA treatment. Moreover, these data suggest that patients receiving UPA had faster therapeutic response times, as seen by earlier meaningful improvement in PROs, compared with ABA-treated patients.

Abbreviations
ABA: Abatacept; bDMARD: Biologic disease-modifying antirheumatic drugs; bDMARD-IR: Biologic disease-modifying antirheumatic drugs inadequate response or intolerant; BL: Baseline; CRP: C-reactive protein; csDMARD: Conventional synthetic disease-modifying antirheumatic drugs; DAS: Disease activity score; DAS28: Disease activity score for 28 joints; EQ-SD: European Quality of Life 5-Dimension 5-Level; FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue; HAQ-DI: Health Assessment Questionnaire Disability Index; HRQOL: Health-related quality of life; IV: Intravenous; JAK: Janus kinase; LSM: Least square mean; MCID: Minimal clinically important difference; MCS: Mental Component Summary; MTX: Methotrexate; PCS: Physical Component Summary; PRO: Patient-reported outcome; PtGA: Patient Global Assessment of Disease Activity; QOL: Quality of life; RA: Rheumatoid arthritis; SF-36: 36-Item Short Form Health Survey; UPA: Upadacitinib; VAS: Visual analog scale; WPAI: Work Productivity and Activity Impairment.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13075-022-02813-x.

Additional file 1: Figure S1. Proportion of Patients Reporting PRO Scores ≥ Normative Values at Baseline and weeks 12 and 24. *ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg); ABA, abatacept; BL, baseline; EQ-SD-SL (index score), EQ-SD S-Level; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire Disability Index; IV, intravenous; LDA, low disease activity; MCS, Mental Component Summary; PCS, Physical Component Summary; PRO, patient-reported outcome; PtGA, Patient Global Assessment of Disease Activity; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib. *P<0.05 for UPA vs ABA. †P=0.05 for UPA vs ABA.

Additional file 2: Figure S2. Proportion of Patients Reporting SF-36 Scores ≥ Normative Values at Baseline and weeks 12 and 24. *ABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1,000 mg); ABA, abatacept; BL, baseline; BP, bodily pain; GH, general health; IV, intravenous; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib; VT, vitality. *P<0.05 for UPA vs ABA.
Acknowledgements
Medical writing services are provided by Brandy Menges and Samantha D. Francis Stuart of Fishawack Facilitate Ltd, part of Fishawack Health, and funded by AbbVie.

Authors' contributions
NT contributed to study concept and study design and analysis plan development and review. NM, JLS, and JP contributed to the study design and analysis plan review. DG and YS contributed to the study design and analysis plan development and conducted the analysis. MB and GCW contributed to the study design and analysis plan review, as well as results interpretation. All authors reviewed and approved the final manuscript.

Funding
This work/study was funded by AbbVie Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. All authors had access to the data results and participated in the development, review, and approval of this abstract. No honoraria or payments were made for authorship.

Availability of data and materials
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. Access is provided to anonymized, patient and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports) from AbbVie-sponsored Phase II-IV global interventional clinical trials conducted in patients (completed as of May 2004, for products and indications approved in either the USA or the European Union), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-sciences/clinical-trials/clinical-trials-data-and-information-sharing-with-qualified-researcher.html.

Declarations
Ethics approval and consent to participate
The protocol was approved by an independent ethics committees or institutional review board at all study sites. All participants provided written informed consent prior to enrollment. The registered clinical trial was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and is consistent with the International Conference on Harmonization Good Clinical Practice and Good Epidemiology Practices, and all applicable local regulatory requirements. All patient data were de-identified and complied with patient confidentiality requirements.

Consent for publication
Not applicable.

Competing interests
MB is a consultant/speaker for AbbVie, Amgen, BMS, Genentech/Roche, Gilead, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi/Regeneron; and shareholder of Johnson & Johnson (parent company of Janssen). GCW has received speaker and consulting fees from AbbVie and BMS. NM, JLS, and JP are employees and stockholders of AbbVie. NT is a former employee of AbbVie and may hold stock. DG and YS are employees of Analysis Group, Inc., which received consulting fees from AbbVie for this study.

Author details
1 Drexel University College of Medicine, Philadelphia, PA, USA. 2 AbbVie Inc, North Chicago, IL, USA. 3 Analysis Group, Inc., Boston, MA, USA. 4 Grace C. Wright MD PC, Association of Women in Rheumatology; United Rheumatology, New York, NY, USA.

Received: 19 July 2021   Accepted: 13 May 2022
Published online: 24 June 2022

References
1. Taylor PC, Moore A, Vasiilescu R, Alver J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685–95.
2. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patient's lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32–40.
3. Radnir H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16(1):R56.
4. Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42.
5. Uhlig T, Loge JH, Kristiansen IS, Kyven TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–7.
6. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kersschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685.
7. Shi Q, Li KJ, Treuer T, Wang BCM, Gaich CL, Lee CH, et al. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD). PLoS One. 2018;13(4):e0193489.
8. Sergeant JC, Hyrich KL, Anderson J, Kopeck-Harding K, Hope HF, Symmons DPM, et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018;20(1):147.
9. Giblyasky A, Galloway J, Kekow J, Zerbini C, de la Vega M, Lee G, et al. Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health Qual Life Outcomes. 2018;16(1):211.
10. Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res. 2012;64(2):206–14.
11. Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603–10.
12. Druce KL, Bhattacharya Y, Jones GT, Macfarlane GJ, Basu N. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;55(10):1786–90.
13. Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21(1):272.
14. Strand V, Tundia N, Bergman M, Oltar A, Durez P, Song IH, et al. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021;60(12):5583–94.
15. Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):263.
16. Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–11.
17. Massarotti EM. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis. Clin Ther. 2008;30(3):429–42.

18. Fleischmann R, Weinblatt ME, Schiff M, Kharina D, Maldonado MA, Nadiarni A, et al. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res. 2016;68(7):907–13.

19. Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, et al. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules. 2020;10(7):1002.

20. Singh JA, Hossain A, Tanjong Ghogomu E, Koth A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016;2016(5):CD012183.

21. Vieira M-C, Zwillich SH, Jansen JP, Smiechowski B, Spureden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016;38(12):2628–41.e5.

22. Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Int J Rheumatol. 2017;2017:8417249.

23. Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–21.

24. Strand V, Boers M, Izeri granddaughter, Kirwan JR, Kven TK. Tugwell PS, et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38(8):1720–7.

25. Kitchen H, B H, L A. Patient-reported outcome measures for rheumatoid arthritis: Minimal important differences review. Arthritis Rheum. 2013;65(Suppl 10):Abstract 2268.

26. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: A preliminary definition. J Rheumatol. 2005;32(10):2016–24.

27. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(Suppl 39):S14–S8.

28. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811–9.

29. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the RAQoL) for rheumatoid arthritis disease activity: A critical appraisal of the existing literature. Expert Rev Clin Immunol. 2011;28(4):537–51.

30. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953–60.

31. Kavango A, Gladman DD, Edwards CJ, Poder A, Liote F, Bird P, et al. THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. Ann Rheum Dis. 2016;75:1.

32. Marra CA, Woolcott JC, Kopecky JA, Shoqan A, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.

33. Hinz A, Kohlmann T, Stobel-Richter Y, Zenger M, Brahler E. The quality of life questionnaires EQ-5D-5L: psychometric properties and normative values for the general German population. Qual Life Res. 2014;23(2):443–7.